Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT-lung phase II trial of sotorasib in unresectable stage III KRAS G12C NSCLC
2021-004576-34Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Progression-free survival at 12 months. Started Dec 2021; status: active.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004576-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004576-34.